FBLG — FibroBiologics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1958777 ·
Last close
$1.06
Market Cap
$5.52M
52W High
$9.60
52W Low
$0.95
ADV30
316,944
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,068,000 | -5,000,000 | 5,938,000 | 1,482,000 | 3,338,000 |
| Dec 2025 | 0 | — | -2,590,000 | -3,244,000 | 9,619,000 | 4,894,000 | 3,463,000 |
| Sep 2025 | 0 | — | -5,038,000 | -5,778,000 | 8,744,000 | 4,867,000 | 8,619,000 |
| Jun 2025 | 0 | — | -4,490,000 | -4,658,000 | 13,907,000 | 8,845,000 | 13,047,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,483,000
Investing CF
$-219,000
Financing CF
$8,517,000
CapEx
$-361,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.04
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-59,164,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-18,472,000
Pretax Income TTM
$-18,680,000
Interest Exp TTM
$208,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,649,000 | -18,646,000 | 9,619,000 | 3,463,000 | — | -16,394,000 |
| Dec 2024 | 0 | -13,737,000 | -11,161,000 | 16,445,000 | 13,710,000 | — | -11,901,000 |
| Dec 2023 | 0 | -8,889,000 | -16,485,000 | 11,821,000 | 10,568,000 | — | -6,401,000 |
| Dec 2022 | 0 | -4,467,000 | -5,121,000 | 4,824,000 | 8,820,000 | — | -4,066,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XTLB | XTL BIOPHARMACEUTICALS LTD | $5.63M | $2.38 | — |
| KAYS | Kaya Holdings, Inc. | $5.39M | $0.01 | — |
| INM | InMed Pharmaceuticals Inc. | $5.70M | $1.72 | — |
| INBP | INTEGRATED BIOPHARMA INC | $5.35M | $0.17 | — |
| BGMS | Bio Green Med Solution, Inc. | $5.33M | $0.96 | — |
News headlines (Yahoo Finance, 1h cache)
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
2026-05-22 12:30 · Yahoo
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
2026-05-18 12:30 · Yahoo
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
2026-05-11 12:30 · Yahoo
FibroBiologics CEO Issues Letter to Shareholders
2026-05-05 12:30 · Yahoo
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
2026-05-04 20:01 · Yahoo
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
2026-05-04 12:30 · Yahoo
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
2026-04-30 21:55 · Yahoo
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
2026-04-30 12:30 · Yahoo
FibroBiologics Compliant with All Nasdaq Listing Requirements
2026-04-20 20:01 · Yahoo
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
2026-04-10 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.